# Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

> **NCT02108418** · PHASE1 · COMPLETED · sponsor: **TaiGen Biotechnology Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TG-2349 as the original formulation
- **DRUG:** TG-2349 as a new capsule formulation

## Key facts

- **NCT ID:** NCT02108418
- **Lead sponsor:** TaiGen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02108418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02108418, "Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02108418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*